Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures.
Long-term bone marrow cultures (LTBMC) from patients with multiple myeloma (MM) and normal donors were analyzed for immunophenotype and cytokine production. Both LTBMC adherent cells from myeloma and normal donor origin expressed CD10, CD13, the adhesion molecules CD44, CD54, vascular cell adhesion molecule 1, very late antigen 2 (VLA-2), and VLA-5, and were positive for extracellular matrix components fibronectin, laminin, and collagen types 3 and 4. LTBMC from myeloma patients and normal donors spontaneously secreted interleukin-6 (IL-6). However, levels of IL-6 correlated with the stage of disease; highest levels of IL-6 were found in LTBMC from patients with active myeloma. To identify the origin of IL-6 production, LTBMC from MM patients and normal donors were cocultured with BM-derived myeloma cells and cells from myeloma cell lines. IL-6 was induced by plasma cell lines that adhered to LTBMC such as ARH-77 and RPMI-8226, but not by nonadhering cell lines U266 and FRAVEL. Myeloma cells strongly stimulated IL-6 secretion in cocultures with LTBMC adherent cells from normal donors and myeloma patients. When direct cellular contact between LTBMC and plasma cells was prevented by tissue-culture inserts, no IL-6 production was induced. This implies that intimate cell-cell contact is a prerequisite for IL-6 induction. Binding of purified myeloma cells to LTBMC adherent cells was partly inhibited by monoclonal antibodies against adhesion molecules VLA-4, CD44, and lymphocyte function-associated antigen 1 (LFA-1) present on the plasma cell. Antibodies against VLA-4, CD29, and LFA-1 also inhibited the induced IL-6 secretion in plasma cell-LTBMC cocultures. In situ hybridization studies performed before and after coculture with plasma cells indicated that LTBMC adherent cells produce the IL-6. These results suggest that the high levels of IL-6 found in LTBMC of MM patients with active disease are a reflection of their previous contact with tumor cells in vivo. These results provide a new perspective on tumor growth in MM and emphasize the importance of plasma cell-LTBMC interaction in the pathophysiology of MM.
Lokhorst
H M
HM
Department of Hematology, University Hospital Utrecht, The Netherlands.
Lamme
T
T
de Smet
M
M
Klein
S
S
de Weger
R A
RA
van Oers
R
R
Bloem
A C
AC
D000911:Antibodies, Monoclonal; D001483:Base Sequence; D001854:Bone Marrow Cells; D002448:Cell Adhesion; D015815:Cell Adhesion Molecules / Q000502:physiology; D002450:Cell Communication; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism; D017931:DNA Primers / Q000737:chemistry; D015870:Gene Expression; D016130:Immunophenotyping; D017403:In Situ Hybridization; D066298:In Vitro Techniques; D015850:Interleukin-6 / Q000378:metabolism*; D008969:Molecular Sequence Data; D009101:Multiple Myeloma / Q000473:pathology*; D010950:Plasma Cells / Q000166:cytology; D012333:RNA, Messenger / Q000235:genetics; D013997:Time Factors
D000911:Antibodies, Monoclonal; D015815:Cell Adhesion Molecules; D016207:Cytokines; D017931:DNA Primers; D015850:Interleukin-6; D012333:RNA, Messenger